Lymphoma, Extranodal NK-T-Cell
"Lymphoma, Extranodal NK-T-Cell" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An extranodal neoplasm, usually possessing an NK-cell phenotype and associated with EPSTEIN-BARR VIRUS. These lymphomas exhibit a broad morphologic spectrum, frequent necrosis, angioinvasion, and most commonly present in the midfacial region, but also in other extranodal sites.
| Descriptor ID |
D054391
|
| MeSH Number(s) |
C04.557.386.480.750.199
|
| Concept/Terms |
Lymphoma, Extranodal NK-T-Cell- Lymphoma, Extranodal NK-T-Cell
- Extranodal NK-T-Cell Lymphomas
- Lymphoma, Extranodal NK T Cell
- Lymphomas, Extranodal NK-T-Cell
- NK-T-Cell Lymphoma, Extranodal
- NK-T-Cell Lymphomas, Extranodal
- Extranodal NK-T-Cell Lymphoma
- Extranodal NK T Cell Lymphoma
Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type- Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type
- Extranodal NK T Cell Lymphoma, Nasal and Nasal Type
- Extranodal NK-T-Cell Lymphoma, Nasal Type
- Extranodal NK T Cell Lymphoma, Nasal Type
- Extranodal NK-T-Cell Lymphoma, Nasal
- Extranodal NK T Cell Lymphoma, Nasal
|
Below are MeSH descriptors whose meaning is more general than "Lymphoma, Extranodal NK-T-Cell".
Below are MeSH descriptors whose meaning is more specific than "Lymphoma, Extranodal NK-T-Cell".
This graph shows the total number of publications written about "Lymphoma, Extranodal NK-T-Cell" by people in this website by year, and whether "Lymphoma, Extranodal NK-T-Cell" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2018 | 3 | 0 | 3 |
| 2019 | 3 | 0 | 3 |
| 2020 | 4 | 0 | 4 |
| 2021 | 1 | 0 | 1 |
| 2023 | 3 | 0 | 3 |
| 2024 | 1 | 0 | 1 |
| 2025 | 1 | 0 | 1 |
| 2026 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Lymphoma, Extranodal NK-T-Cell" by people in Profiles.
-
Risk-Adapted Combined-Modality Therapy in Early-Stage Extranodal Natural Killer-/T-Cell Lymphoma: A Markov Model-Based Cost-Effectiveness Analysis. JCO Glob Oncol. 2026 Jan; 12:e2400435.
-
Survival Benefit of Adjuvant Radiation Therapy Following Asparaginase-Based Chemotherapy in Patients With Chemoresponsive Advanced-Stage Extranodal NK/T Cell Lymphoma: A Multicenter Study Using the China Lymphoma Collaborative Group Database. Int J Radiat Oncol Biol Phys. 2026 Feb 01; 124(2):428-440.
-
Genomic features reveal potential benefit of adding anti-PD-1 immunotherapy to treat non-upper aerodigestive tract natural killer/T-cell lymphoma. Leukemia. 2024 04; 38(4):829-839.
-
Evidence of cure for extranodal nasal-type natural killer/T-cell lymphoma with current treatment: an analysis of the CLCG database. Haematologica. 2023 09 01; 108(9):2467-2475.
-
Outcome and risk prediction of early progression in patients with extranodal natural killer/T cell lymphoma from the CLCG study. Ann Hematol. 2023 Sep; 102(9):2459-2469.
-
Clinical characteristics, treatment, and survival of 30 patients with gastrointestinal natural killer/T-cell lymphoma. Cancer Rep (Hoboken). 2023 05; 6(5):e1800.
-
Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter study. Ann Hematol. 2021 Oct; 100(10):2529-2539.
-
Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) study. Leukemia. 2021 06; 35(6):1671-1682.
-
Risk-based, response-adapted therapy for early-stage extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: A China Lymphoma Collaborative Group study. Am J Hematol. 2020 09; 95(9):1047-1056.
-
First-line non-anthracycline-based chemotherapy for extranodal nasal-type NK/T-cell lymphoma: a retrospective analysis from the CLCG. Blood Adv. 2020 07 14; 4(13):3141-3153.